Stockscreener 앱 받기
6.10
0.07%
0.05
전일 마감가:
$6.05
열려 있는:
$5.865
하루 거래량:
5,969
Relative Volume:
0.02
시가총액:
$33.24M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+9.68%
1개월 성능:
+9.88%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.865
$6.09
1주일 범위
$5.30
$6.10
52주 변동 폭
$4.71
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
명칭
Vyome Holdings Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
HIND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
6.09 | 33.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.74 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.57 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.54 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.40 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.00 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vyome Holdings Inc 주식(HIND)의 최신 뉴스
Comparing Anzu Special Acquisition Corp I (NASDAQ:ANZUW) & Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - FinancialContent
Vyome Holdings Elects Directors at Annual Meeting - TipRanks
Head-To-Head Contrast: Vyome (NASDAQ:HIND) & TranS1 (OTCMKTS:BAXSQ) - Defense World
ReShape Lifesciences : trade; to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate UpdateForm 8-K/A - MarketScreener
Tincoff John M. Iii Net Worth (2025) - GuruFocus
ReShape Lifesciences (OTCMKTS:RSLSD) versus Vyome (NASDAQ:HIND) Financial Survey - Defense World
Will Vyome's Topical Gel Be The First FDA-Approved Treatment For Cancer Wounds? - RTTNews
Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Acquires AI Startup Oculo, Inc. - TipRanks
HIND Analyst Forecasts - Quiver Quantitative
Vyome Holdings acquires Oculo Health - Medical Buyer
Vyome Holdings Acquires MIT Spinout Oculo Health, Launches AI Psychiatrist Business Unit - Sahyadri Startups
Vyome Holdings Acquires MIT AI Spinout Oculo Health - citybiz
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics By Investing.com - Investing.com South Africa
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics - Investing.com Nigeria
Vyome Holdings acquires MIT AI spinout Oculo Health - MarketScreener
Vyome shares surge after encouraging preclinical data for eye treatment - MSN
BC-Most Active Stocks - upstatetoday.com
Why Is BBAI Stock Falling Today? - Stocktwits
HIND Stock Rallies 70% Pre-Market Today Find Out Why - Menafn
HIND Stock: Growth or Bubble? - StocksToTrade
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Asianet Newsable
Vyome Holdings (HIND) Skyrockets Over 50% on Breakthrough Uveitis Treatment News - RagingBull
Vyome stock soars after positive preclinical results for eye drug - Investing.com India
Vyome stock soars after positive preclinical results for eye drug By Investing.com - Investing.com Nigeria
Morning Market Movers: SPRC, HIND, SQFT, FGNX See Big Swings - RTTNews
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity - Business Wire
Vertiv’s Stock Surge: Will it Last? - StocksToTrade
Vyome Holdings Appoints Dr. Richard Fahrner as CTO and Dr. Tamara Agajanov, MD, as SVP – Clinical Development - citybiz
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies - PharmiWeb.com
Vyome Holdings strengthens leadership team with industry veterans as it plans pivotal trial studies - MarketScreener
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com Nigeria
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome Therapeutics2025 Latest Shareholding - Tracxn
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com India
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome Holdings completes merger with Vyome Therapeutics and files financials By Investing.com - Investing.com Canada
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome Holdings, Inc. (HIND) Company Profile & Facts - Yahoo
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
Vyome Holdings Inc (HIND) 재무 분석
Vyome Holdings Inc (HIND)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.03%
0.32%
자본화:
|
볼륨(24시간):